BEUDAMED
    FDA Adverse Event Injury Summary report: N

    BINAXNOW G6PD

    MDR report key: 9482180 · Received December 17, 2019

    Report

    Report Number
    1221359-2019-00088
    Event Type
    Injury
    Date Received
    December 17, 2019
    Report Date
    January 15, 2020
    Manufacturer
    ABBOTT DIAGNOSTICS SCARBOROUGH, INC.
    Product Code
    JBF
    UDI-DI
    10811877010705
    PMA / PMN Number
    K080003
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    PK
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL

    Narratives

    Additional Manufacturer Narrative · 0

    TESTING WAS PERFORMED AT ABBOTT DIAGNOSTIC SCARBOROUGH, INC. ON RETAINED KIT LOT 107481 AND 107776 WITH THE FOLLOWING INTERNAL CONTROL SAMPLES: POSITIVE CONTROL - 20 U/DL DEFICIENT CONTROL (HEPARIN OR EDTA PER CUSTOMER SAMPLE TYPE) AND NEGATIVE CONTROL - PRESUMED NORMAL WHOLE BLOOD (HEPARIN OR EDTA) ALL TEST RESULTS WERE VALID AND PERFORMED AS EXPECTED. ADDITIONALLY, THE MANUFACTURING BATCH RECORDS FOR LOT 107481 AND 107776 WERE REVIEWED. THESE LOT MET THE REQUIRED RELEASE SPECIFICATIONS. A REVIEW OF THE COMPLAINTS REPORTED AS (CONFIRMED AND UNCONFIRMED) CONFLICTING RESULTS RELATED TO LOT NUMBER 107481 AND LOT NUMBER 107776 SHOWED THAT THE COMPLAINT RATE IS 0.008% FOR EACH LOT. THE EVIDENCE AVAILABLE DOES NOT INDICATE THAT THE PRODUCT IS PERFORMING OUTSIDE LABEL CLAIMS. ABBOTT DIAGNOSTICS SCARBOROUGH, INC. WAS UNABLE TO DETERMINE THE EXACT ROOT CAUSE OF THE REPORTED ISSUE.THE AVAILABLE EVIDENCE SUGGESTS THAT THESE DEVICE LOTS ARE PERFORMING WITHIN LABELED CLAIMS.

    Additional Manufacturer Narrative · 1

    DUE TO A SPECIALIZED CONTROL MANUFACTURING PROCESS, RETAIN TESTING WAS UNABLE TO BE PERFORMED BY REPORT SUBMISSION DUE DATE. TESTING IS SCHEDULED AT ABBOT DIAGNOSTICS SCARBOROUGH, INC. ON RETAINED KIT LOT 10748 WITH POSITIVE (DEFICIENT) AND NEGATIVE (NORMAL) INTERNAL HEPARIN AND EDTA CONTROL SAMPLES. TEST RESULTS AND INVESTIGATION CONCLUSION WILL BE COMMUNICATED IN A SUPPLEMENTAL REPORT. THE MANUFACTURING BATCH RECORDS FOR LOT 107481 WERE REVIEWED. THIS LOT MET THE REQUIRED RELEASE SPECIFICATIONS. A REVIEW OF THE COMPLAINTS REPORTED AS (CONFIRMED AND UNCONFIRMED) CONFLICTING RESULTS RELATED TO LOT NUMBER 107481 SHOWED THAT THE COMPLAINT RATE IS 0.008%. THE EVIDENCE AVAILABLE DOES NOT INDICATE THAT THE PRODUCT IS PERFORMING OUTSIDE LABEL CLAIMS. THE AVAILABLE EVIDENCE SUGGESTS THAT THIS DEVICE LOT IS PERFORMING WITHIN LABELED CLAIMS.

    Description of Event or Problem · 1

    A CUSTOMER IN PAKISTAN SUBMITTED A COMPLAINT OF DISCREPANT RESULTS WITH BINAXNOW G6PD. THE CUSTOMER REPORTED GENERATING A DEFICIENT RESULT WITH THE BINAXNOW G6PD ASSAY (SAMPLE TYPE NOT SPECIFIED). THE CUSTOMER STATED THAT ADDITIONAL PATIENT INFORMATION (CBC/PERIPHERAL BLOOD SMEAR, PATIENT HISTORY) WERE NOT SUGGESTIVE OF G6PD DEFICIENCY. THE BINAXNOW G6PD TEST WAS REPEATED, GENERATING NORMAL RESULTS. IT IS UNKNOWN IF THE REPEAT TESTING WAS PERFORMED ON THE SAME SAMPLE AND BINAXNOW G6PD KIT LOT. CONFIRMATION TESTING AND RESULTS ARE UNKNOWN. NO INJURY TO THE PATIENT WAS REPORTED. ATTEMPTS TO GAIN ADDITIONAL PATIENT INFORMATION WERE NOT SUCCESSFUL. LIMITATIONS PER THE PRODUCT INSERT: "LIMITATIONS THE BINAXNOW® G6PD TEST IS DESIGNED TO DISTINGUISH NORMAL LEVELS OF G6PD ENZYME ACTIVITY FROM DEFICIENT ENZYME ACTIVITY AND CANNOT BE USED TO ASSESS THE DEGREE OF DEFICIENCY. SAMPLES WHICH GENERATE A DEFICIENT RESULT ON THIS TEST SHOULD BE ASSAYED ON A QUANTITATIVE G6PD TEST. ABNORMALLY LOW AND HIGH HEMATOCRIT LEVELS CAN AFFECT TEST PERFORMANCE. G6PD IS NORMALLY FOUND IN THE RED BLOOD CELLS, AND A LOW HEMATOCRIT IS AN INDICATOR THAT THE NUMBER OF RED CELLS IS LOW IN A SPECIFIC VOLUME OF BLOOD. THEREFORE, A LOW SAMPLE HEMATOCRIT INCREASES THE RISK OF A FALSE DEFICIENT RESULT FOR AN OTHERWISE NORMAL SAMPLE BECAUSE THERE ARE LESS RED CELLS AND HENCE LESS G6PD. CONVERSELY, A SIMILAR SITUATION CAN EXIST WITH A SAMPLE HAVING A HIGH HEMATOCRIT WHERE A HIGH NUMBER OF RED CELLS ARE PRESENT COMPARED TO A NORMAL SAMPLE. IN THIS CASE, A HIGH HEMATOCRIT INCREASES THE RISK OF A FALSE NORMAL RESULT FOR AN OTHERWISE DEFICIENT SAMPLE." CONFLICTING RESULTS INDICATE A MALFUNCTION OF ONE OF THE TESTS AS IT IS EXPECTED THAT TESTING THE SAME PATIENT SAMPLE OR A SECOND SAMPLE FROM THE SAME PATIENT TESTED ON THE SAME DAY AS THE ORIGINAL SAMPLE WOULD RETURN THE SAME RESULT. IN A WORST-CASE SCENARIO, A FALSE NORMAL RESULT COULD HAVE OCCURRED. IN THE CASE OF A FALSE NORMAL RESULT, THE RISK OF AN UNEXPLAINED CONFLICTING RESULT COULD CAUSE OR CONTRIBUTE TO A DEATH OR SERIOUS INJURY AND IS THEREFORE REPORTABLE AS A SERIOUS INJURY.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1277726 BINAXNOW G6PD IVD FOR G6PD DEFICIENCY JBF ABBOTT DIAGNOSTICS SCARBOROUGH, INC. 107481 10811877010705

    Patients

    Seq Age Sex Outcome Treatment
    1